[Corrigendum] ND‑09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR‑ABL signaling. [PDF]
Liu YH, Zhu M, Lei PP, Pan XY, Ma WN.
europepmc +1 more source
T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy. [PDF]
Hsu MT +3 more
europepmc +1 more source
Advances in Targeting BCR-ABL<sup>T315I</sup> Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules. [PDF]
Tuzikiewicz A +3 more
europepmc +1 more source
[Allogeneic hematopoietic stem cell transplantation for the treatment of BCR::ABL-negative neutrophilic myeloid neoplasms: a clinical analysis of 12 cases]. [PDF]
Han TT +11 more
europepmc +1 more source
3D-QSAR Design of New Bcr-Abl Inhibitors Based on Purine Scaffold and Cytotoxicity Studies on CML Cell Lines Sensitive and Resistant to Imatinib. [PDF]
Cabezas D +13 more
europepmc +1 more source
Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia. [PDF]
Luo Z +15 more
europepmc +1 more source
Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors: A real-world experience in Africa. [PDF]
Ayalew ZS +8 more
europepmc +1 more source
CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells. [PDF]
Khamidullina AI +17 more
europepmc +1 more source
Co-Occurrence of Jak2-Positive Myelofibrosis and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. [PDF]
Paciaroni K +8 more
europepmc +1 more source

